Colonic thioguanine pro-drug: Investigation of microbiome and novel host metabolism

ABSTRACT Thiopurines are analogues of endogenous purines. They are pro-drugs which require the purine salvage pathway to convert them to the active drug nucleotides (TGN). These drugs are used to maintain clinical remission in patients with inflammatory bowel diseases. In our recent Gut paper, we showed that thioguanine worked quickly to improve colitis in the absence in the host animal of the key guanine salvage enzyme, hypoxanthine-guanine-phosphoribosyltransferase (HPRT). Current evidence favours the proposition that active drug delivery to the host lacking HPRT requires translocation of TGN-loaded bacteria across the inflamed mucosal barrier, and most likely delivery by phagocytosis. Alternatively, the efficacy of thioguanine in treating colitis could be mediated by modulation of the community of the microbiota in the intestine, or there are novel host pathways for conversion of the thioguanine pro-drug to TGN.

[1]  J. Begun,et al.  The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis. , 2017, Seminars in cell & developmental biology.

[2]  R. Eri,et al.  Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[3]  C. Mulder,et al.  The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease , 2016, Inflammatory bowel diseases.

[4]  M. Neurath,et al.  Microbiota: relevant player in thiopurine metabolisation? , 2016 .

[5]  D. Aguirre de Cárcer,et al.  Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism , 2016, Gut.

[6]  A. Perkins,et al.  High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22 , 2016, Scientific Reports.

[7]  M. Daly,et al.  Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk. , 2016, Immunity.

[8]  T. Florin,et al.  Splitting a Therapeutic Dose of Thioguanine May Avoid Liver Toxicity and Be an Efficacious Treatment for Severe Inflammatory Bowel Disease: A 2-Center Observational Cohort Study , 2014, Inflammatory bowel diseases.

[9]  K. Faber,et al.  Suppression of p21Rac Signaling and Increased Innate Immunity Mediate Remission in Crohn’s Disease , 2014, Science Translational Medicine.

[10]  R. Xavier,et al.  Autophagy at the crossroads of metabolism and cellular defense , 2013, Current opinion in gastroenterology.

[11]  D. Crane,et al.  Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins , 2013, The Journal of experimental medicine.

[12]  H. Jinnah,et al.  A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity , 2012, Gut.

[13]  D. Kuik,et al.  Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  G. Radford-Smith,et al.  An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity , 2010, Mucosal Immunology.

[15]  C. Goodnow,et al.  Aberrant Mucin Assembly in Mice Causes Endoplasmic Reticulum Stress and Spontaneous Inflammation Resembling Ulcerative Colitis , 2008, PLoS medicine.

[16]  B. Bonaz,et al.  A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease , 2007, Wiener klinische Wochenschrift.

[17]  T. Florin,et al.  Thiopurine Therapies: Problems, Complexities, and Progress With Monitoring Thioguanine Nucleotides , 2005, Therapeutic drug monitoring.

[18]  S. Targan,et al.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.

[19]  S. Targan,et al.  Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine , 2003, American Journal of Gastroenterology.

[20]  T. Florin,et al.  6‐thioguanine: a new old drug to procure remission in inflammatory bowel disease , 2003, Internal medicine journal.

[21]  P. Nygaard,et al.  Cloning and characterization of the gsk gene encoding guanosine kinase of Escherichia coli , 1995, Journal of bacteriology.

[22]  T. Chan.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity. , 1979, Proceedings of the National Academy of Sciences of the United States of America.